As summarized in Figure 2B, median overall survivals were consistently higher in breast cancer patients with absence of h-prune amplification (median OS: 96 months in comparison to 59 months of patients with h-prune polysomy) and negative immunostaining for pERK1-2 (median OS: 95 months in comparison to 43 months of patients with pERK1-2+ tumours) and survivin (median OS: 97 months in comparison to 45 months of patients with survivin overexpression). This evidence concerns the gene BIRC5 and neoplasm.